(0.82%) 5 059.54 points
(0.75%) 38 189 points
(1.43%) 15 829 points
(-0.03%) $78.98
(5.43%) $2.04
(0.09%) $2 313.10
(0.59%) $26.91
(0.82%) $962.75
(-0.08%) $0.932
(-0.33%) $10.99
(-0.11%) $0.798
(-1.37%) $91.98
Live Chart Being Loaded With Signals
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally...
Stats | |
---|---|
今日成交量 | 8.12M |
平均成交量 | 9.28M |
市值 | 15.75B |
EPS | $0 ( 2024-02-14 ) |
下一个收益日期 | ( $0.510 ) 2024-05-08 |
Last Dividend | $0.0850 ( 2017-11-27 ) |
Next Dividend | $0 ( N/A ) |
P/E | -28.10 |
ATR14 | $0.0130 (0.09%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-05 | Kalif Eliyahu Sharon | Buy | 21 387 | Ordinary Shares |
2024-03-05 | Kalif Eliyahu Sharon | Buy | 52 320 | Ordinary Shares |
2024-03-06 | Kalif Eliyahu Sharon | Sell | 77 550 | Ordinary Shares |
2024-03-05 | Kalif Eliyahu Sharon | Sell | 21 387 | Restricted Share Units |
2024-03-05 | Kalif Eliyahu Sharon | Sell | 52 320 | Restricted Share Units |
INSIDER POWER |
---|
16.80 |
Last 98 transactions |
Buy: 2 305 980 | Sell: 1 612 593 |
音量 相关性
Teva Pharmaceutical 相关性 - 货币/商品
Teva Pharmaceutical 财务报表
Annual | 2023 |
营收: | $15.85B |
毛利润: | $7.65B (48.25 %) |
EPS: | $-0.500 |
FY | 2023 |
营收: | $15.85B |
毛利润: | $7.65B (48.25 %) |
EPS: | $-0.500 |
FY | 2022 |
营收: | $14.93B |
毛利润: | $6.97B (46.72 %) |
EPS: | $-2.12 |
FY | 2021 |
营收: | $15.88B |
毛利润: | $7.60B (47.83 %) |
EPS: | $0.380 |
Financial Reports:
No articles found.
Teva Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.00188 | 1987-02-23 |
Last Dividend | $0.0850 | 2017-11-27 |
Next Dividend | $0 | N/A |
Payout Date | 2017-12-12 | |
Next Payout Date | N/A | |
# dividends | 125 | -- |
Total Paid Out | $11.76 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.26 | -- |
Div. Sustainability Score | 4.54 | |
Div.Growth Potential Score | 0.535 | |
Div. Directional Score | 2.54 | -- |
Year | Amount | Yield |
---|---|---|
1987 | $0.00802 | 1.94% |
1988 | $0.00964 | 2.40% |
1989 | $0.00807 | 1.81% |
1990 | $0.00919 | 1.23% |
1991 | $0.00938 | 1.28% |
1992 | $0.0105 | 0.75% |
1993 | $0.0161 | 0.56% |
1994 | $0.0175 | 0.46% |
1995 | $0.0271 | 0.90% |
1996 | $0.0250 | 0.43% |
1997 | $0.0310 | 0.50% |
1998 | $0.0411 | 0.68% |
1999 | $0.0276 | 0.52% |
2000 | $0.0413 | 0.47% |
2001 | $0.0648 | 0.39% |
2002 | $0.0906 | 0.59% |
2003 | $0.163 | 0.83% |
2004 | $0.201 | 0.69% |
2005 | $0.269 | 0.92% |
2006 | $0.306 | 0.69% |
2007 | $0.385 | 1.23% |
2008 | $0.503 | 1.07% |
2009 | $0.605 | 1.42% |
2010 | $0.748 | 1.29% |
2011 | $0.901 | 1.71% |
2012 | $1.034 | 2.40% |
2013 | $1.278 | 3.44% |
2014 | $1.366 | 3.39% |
2015 | $1.360 | 2.42% |
2016 | $1.360 | 2.08% |
2017 | $0.850 | 2.27% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
NCZ | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.79% | 8.50 |
VGI | Dividend Royal | 2024-02-09 | Monthly | 13 | 7.36% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
PCF | Dividend King | 2023-12-18 | Monthly | 38 | 7.05% | 8.50 |
ZTR | Dividend Royal | 2024-02-09 | Monthly | 37 | 8.35% | 8.50 |
PVL | Dividend King | 2023-11-15 | Monthly | 14 | 9.37% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | -0.0353 | 1.500 | -0.706 | -1.058 | [0 - 0.5] |
returnOnAssetsTTM | -0.0129 | 1.200 | -0.429 | -0.514 | [0 - 0.3] |
returnOnEquityTTM | -0.0762 | 1.500 | -1.958 | -2.94 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 1.019 | 0.800 | 9.90 | 7.92 | [1 - 3] |
quickRatioTTM | 0.542 | 0.800 | -1.520 | -1.216 | [0.8 - 2.5] |
cashRatioTTM | 0.263 | 1.500 | 9.65 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.464 | -1.500 | 2.27 | -3.41 | [0 - 0.6] |
interestCoverageTTM | 0.914 | 1.000 | -0.773 | -0.773 | [3 - 30] |
operatingCashFlowPerShareTTM | 1.220 | 2.00 | 9.59 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.751 | 2.00 | 9.62 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 2.68 | -1.500 | 10.00 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.482 | 1.000 | 5.29 | 5.29 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0593 | 1.000 | -0.814 | -0.814 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0679 | 1.000 | -0.734 | -0.734 | [0.2 - 2] |
assetTurnoverTTM | 0.364 | 0.800 | -0.904 | -0.723 | [0.5 - 2] |
Total Score | 4.54 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -28.04 | 1.000 | -2.93 | 0 | [1 - 100] |
returnOnEquityTTM | -0.0762 | 2.50 | -1.259 | -2.94 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.751 | 2.00 | 9.75 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 1.220 | 2.00 | 9.59 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | -0.323 | 1.500 | -5.49 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0863 | 1.000 | -0.342 | 0 | [0.1 - 0.5] |
Total Score | 0.535 |
Teva Pharmaceutical
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。